A5058782853- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Head and Neck Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Oral health in cancer treatment
- Neuroendocrine Tumor Research Advances
- Gallbladder and Bile Duct Disorders
- Vascular Tumors and Angiosarcomas
- Cancer Treatment and Pharmacology
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Neuroblastoma Research and Treatments
- Multiple Myeloma Research and Treatments
- Cancer Research and Treatments
- Breast Cancer Treatment Studies
Japan Clinical Cancer Research Organization
2019-2025
Tokyo National Hospital
2022
National Cancer Center
2022
Hiroshima University Hospital
2017-2019
Hiroshima University
2017-2019
Hiroshima City University
2019
Kobe University Hospital
2016
Obihiro University of Agriculture and Veterinary Medicine
2015
Kobe University
2009-2010
Mie University
1999-2004
Etoposide plus cisplatin (EP) and irinotecan (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC).To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) patients with NEC the digestive system.This open-label phase 3 randomized clinical trial enrolled chemotherapy-naive aged 20 to 75 years who had recurrent unresectable (according 2010 World Health Organization classification system) arising from gastrointestinal...
We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC).Patients untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was primary endpoint. The major secondary end-points included progression-free (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, adverse events. sample size...
PURPOSE Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m once day 1, then 2g/m days 2-7] × six) to patients showing a poor response (PrRsp) preoperative chemotherapy with methotrexate, doxorubicin, and cisplatin (MAP) improves their prognoses. In this Japan Clinical Oncology Group (JCOG) study, JCOG0905, we aimed investigate the efficacy safety of IF in PrRsp. METHODS JCOG0905 is multicenter, open-label,...
This study aimed to evaluate the long-term prognosis of patients with peripheral small ground-glass opacity-dominant lung cancer after sublobar resection. We have already reported 5-year safety and efficacy resection report outcomes a 10-year follow-up period.Between May 2009 April 2011, 333 radiologically noninvasive were enrolled from 51 institutions (median age, 62 years at registration) followed up until 6, 2021. Of these patients, resections wedge as first choice performed in 314 (258...
Distinguishing between mucosal and submucosal cancers is important for selecting the optimal treatment patients with esophageal squamous cell carcinoma (ESCC); however, standard procedures diagnosing cancer invasion depth have not yet been determined.To evaluate diagnostic performance of endoscopic ultrasonography (EUS) after conventional endoscopy evaluation ESCC depth.This prospective single-arm confirmatory study comprising 372 T1 was conducted at 41 secondary or tertiary hospitals in...
382 Background: Capecitabine is usually used for patients with curatively resected biliary tract cancer (BTC) in EU and US, but no clear survival benefit has been shown phase III trials. S-1, an oral fluoropyrimidine derivative, promising efficacy, a mild toxicity profile, advanced BTC. The aim of this trial was to confirm whether adjuvant S-1 therapy might improve the overall (OS) Methods: This open-label, multicenter, randomized conducted 38 Japanese hospitals. Eligible were aged 20 80...
In Japan, the Act on Safety of Regenerative Medicine regulates unapproved regenerative medicine. Other nations market medicine products, bypassing regulatory approval. To identify orthopedic medicine, we have used data based Act. Platelet-rich plasma was often used. The common target knee. Prices averaged $2,490.
The development of PD-1 pathway inhibitors has dramatically altered the treatment advanced/recurrent non-small-cell lung cancer patients. However, prognostic significance their ongoing usage is controversial, especially for patients who have not progressed a period time. If discontinuation no negative impact on survival, suspension may reduce side effects from toxicity and help alleviate economic burdens health insurance systems This randomized controlled trial enrolls responded well to >12...
This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior the standard Adriamycin ifosfamide (AI) in terms of overall survival (OS) patients soft tissue sarcoma (STS).Patients localised high-risk STS extremities or trunk were receive AI GD. The treatments repeated for three preoperative and two postoperative courses. primary endpoint was OS.Among 143 enrolled who received (70 patients) compared GD (73...
The exposure of human lymphoid leukemia Molt 4B cells to phytol which was isolated from Lolium multiflorum Lam and identified by MS, 1H- 13C-NMR, led both growth inhibition the induction programmed cell death (apoptosis). Morphological change showing apoptotic bodies observed in treated with phytol. fragmentation DNA oligonucleosomal-sized fragments that are characteristics apoptosis be concentration- time-dependent. These findings suggest results cells.
Management of elderly patients with early gastric cancer is an important issue in aging society such as Japan. While endoscopic resection recommended the standard treatment for cancers extremely low risk lymph node metastasis (<1%), gastrectomy lymphadenectomy other even patients. Endoscopic submucosal dissection most procedure because its high ability 'en bloc' resection. can reportedly provide favorable short-term outcomes In terms patient prognosis, importance considering patients'...
TPS621 Background: Biliary tract cancer (BTC) is a highly lethal disease. The prognosis remains poor even after macroscopically curative resection due to the high recurrence rate. Therefore, developing effective adjuvant therapy essential improve treatment outcomes. In 2021, phase III trial (JCOG1202: ASCOT) showed superiority of S-1 chemotherapy surgery alone in overall survival (OS) BTC patients with (hazard ratio [HR] 0.694, 95% confidence interval [CI]: 0.514–0.935; p=0.008)....
ObjectivesCisplatin plus irinotecan has been considered as the standard therapy in younger (<70 years old) patients for extensive-disease small-cell lung cancer (ED-SCLC) Japan. However, there is a lack of high-quality evidence use elderly with ED-SCLC. This study aimed to demonstrate that carboplatin (CI) improves overall survival (OS) ED-SCLC.Materials and methodsThis was randomized Phase II/III trial which enrolled Patients were CI or etoposide (CE) arm 1:1 ratio. The CE group...
4017 Background: FOLFIRINOX, consisting of leucovorin (LV), fluorouracil (FU), irinotecan (IRI) and oxaliplatin (L-OHP), GnP, gemcitabine (GEM) plus nab-paclitaxel (nPTX), have shown superior efficacy over GEM in patients (pts) with metastatic pancreatic cancer. Although several studies reported the FOLFIRINOX or GnP for pts locally advanced cancer (LAPC), no randomized controlled trial to compare two regimens has been conducted those pts. To select most promising chemotherapy LAPC, a phase...
Abstract Among early-stage lung cancers that show ground-glass nodules on chest computed tomography, the cancer surgical study group of Japan Clinical Oncology Group previously reported ≤2 cm with a consolidation/tumor ratio ≤0.25 were considered radiologically non-invasive low risk metastasis. However, there is no consensus based high-quality evidence about optimal timing intervention for cancers. In June 2020, we launched multi-institutional, single-arm confirmatory trial to evaluate...